School of Women's & Children's Health, UNSW Medicine, University of New South Wales, Sydney, Australia.
Department of Immunology and Infectious Diseases, Sydney Children's Hospital, Randwick, Australia.
Pediatr Nephrol. 2020 Sep;35(9):1563-1573. doi: 10.1007/s00467-019-04316-5. Epub 2019 Aug 15.
The global spread of multidrug-resistant organisms has led to an increase in urinary tract infections (UTIs) in children that are difficult to treat. This review explores the current literature regarding multidrug-resistant UTIs in childhood and proposes an approach to management. Multidrug-resistant organisms include a wide range of potential urinary tract pathogens and, while most literature on drug resistance in UTIs during childhood has focused on extended-spectrum beta-lactamase producing organisms, in this review, we have included a discussion of multidrug resistance including and beyond beta-lactamase production. We provide definitions for multidrug-resistant organisms in line with current consensus guidelines and summarise clinically relevant mechanisms of resistance. Additionally, in this review, we outline the global epidemiology of multidrug-resistant UTIs in children, summarising published prevalence rates, which range from 5 to 90% in different settings. Finally, we also critically review the evidence on risk factors for colonisation and infection of the urinary tract with multidrug-resistant organisms, including prior antibiotic use, hospitalisation and underlying urological malformations. We also highlight multidrug-resistant UTI occurring in children without any identifiable risk factors, reflecting an increasing prevalence of colonisation with these organisms in the general community. Taken as a whole, this emphasises a need for careful and evidence-based use of antibiotics when treating UTIs in children and, to aide clinicians, we have outlined here potential management strategies for when infection with a multidrug-resistant organism is suspected or confirmed.
全球耐多药生物体的传播导致儿童尿路感染(UTI)的增加,这些感染难以治疗。本综述探讨了儿童耐多药尿路感染的当前文献,并提出了一种管理方法。耐多药生物体包括广泛的潜在尿路病原体,虽然大多数关于儿童尿路感染中药物耐药性的文献都集中在产生超广谱β-内酰胺酶的生物体上,但在本综述中,我们还讨论了耐多药性,包括但不限于β-内酰胺酶的产生。我们根据当前的共识指南为耐多药生物体提供了定义,并总结了与临床相关的耐药机制。此外,在本综述中,我们概述了儿童耐多药尿路感染的全球流行病学,总结了不同环境下发表的流行率,范围从 5%到 90%不等。最后,我们还批判性地审查了与耐多药生物体引起尿路感染的定植和感染相关的风险因素的证据,包括先前使用抗生素、住院和潜在的尿路畸形。我们还强调了在没有任何可识别风险因素的情况下发生的耐多药性 UTI,这反映了这些生物体在普通人群中定植的流行率不断增加。总的来说,这强调了在治疗儿童尿路感染时需要谨慎和基于证据的使用抗生素,为了帮助临床医生,我们在这里概述了在怀疑或确认感染耐多药生物体时的潜在管理策略。